Zai Lab FY2025 EPS Estimate Increased by Cantor Fitzgerald

Zai Lab Limited (NASDAQ:ZLAB) – Cantor Fitzgerald lifted their FY2025 earnings estimates for shares of Zai Lab in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($0.82) per share for the year, up from their prior forecast of ($1.46). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

A number of other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, March 13th. Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price objective for the company. Finally, Bank of America reaffirmed a “neutral” rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Zai Lab Trading Down 2.7%

ZLAB opened at $28.62 on Wednesday. The stock has a market capitalization of $3.16 billion, a P/E ratio of -10.33 and a beta of 1.04. The stock has a 50-day moving average price of $32.62 and a 200-day moving average price of $29.73. Zai Lab has a 12-month low of $16.01 and a 12-month high of $39.77.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the fourth quarter valued at about $29,000. Pictet Asset Management Holding SA purchased a new position in Zai Lab during the 4th quarter valued at about $31,000. Caitong International Asset Management Co. Ltd bought a new position in Zai Lab during the 1st quarter valued at approximately $75,000. Barclays PLC raised its position in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after purchasing an additional 2,856 shares during the last quarter. Finally, Advisors Preferred LLC purchased a new stake in Zai Lab in the 1st quarter worth approximately $110,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Activity

In other news, CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the sale, the chief executive officer now owns 494,117 shares of the company’s stock, valued at approximately $17,032,212.99. This represents a 9.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Yajing Chen sold 924 shares of Zai Lab stock in a transaction on Friday, April 4th. The stock was sold at an average price of $33.11, for a total transaction of $30,593.64. Following the completion of the transaction, the chief financial officer now directly owns 27,047 shares in the company, valued at approximately $895,526.17. The trade was a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 138,744 shares of company stock valued at $4,685,294. Insiders own 13.88% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.